Lupin Pharmaceuticals

Global pharmaceutical manufacturer and distributor

Lupin Pharmaceuticals

Global pharmaceutical manufacturer and distributor

Overview

Lupin Limited is a global pharmaceutical company that develops and sells branded and generic medicines, complex generics, biotechnology products, and active pharmaceutical ingredients distributed in over 100 markets. It covers therapy areas such as respiratory, cardiovascular, diabetes, infections, GI, CNS, and women’s health, with products in tablets, capsules, injectables and other dosage forms. It operates 15 manufacturing sites and 7 research centers, and runs subsidiaries like Lupin Diagnostics, Lupin Digital Health, and Lupin Manufacturing Solutions to support its offerings. Its goal is to improve patient health outcomes by expanding access to high-quality medicines and strengthening its research, manufacturing, and digital health capabilities worldwide.

Work here?Claim your company

About Lupin Pharmaceuticals

Simplify's Rating

Why Lupin Pharmaceuticals is rated

B-

Rated B on Competitive Edge

Rated B on Growth Potential

Rated C on Differentiation

Industries

Healthcare

Company Size

10,001+

Company Stage

IPO

Headquarters

Mumbai, India

Founded

1968

Get referred to Lupin Pharmaceuticals

See people who can refer or advise you

Simplify's take

What believers are saying

November 2026 FDA approvals for Firdapse, Sugammadex, Pitolisant, and Eribulin broaden US revenue streams.
Apixaban oral suspension received tentative FDA approval in Q2 FY2027, opening a differentiated 505(b)(2) launch.
China's November 2026 oseltamivir approval and YUVEZZI licensing expand Lupin beyond US generics.

What critics are saying

Astellas litigation cost Lupin $90 million and runs through September 2027 on mirabegron.
Tolvaptan and mirabegron erosion cut Q2 FY2027 margins to 25.1%, pressuring FY2028 earnings.
Pithampur Unit II remains under remediation in November 2026; a warning letter would imperil launches.

What makes Lupin Pharmaceuticals unique

Lupin combines India scale, US generics, and biosimilars across 100 markets, as of 2026.
November 2026: VISUfarma secured YUVEZZI Europe rights, extending Lupin's ophthalmology platform.
Its first-to-file USANDA engine produced 353 approvals from 429 filings by September 2026.

Help us improve and share your feedback! Did you find this helpful?

Funding

Total Funding

$50M

Above

Industry Average

Funded Over

1 Rounds

Post IPO Equity funding comparison data is currently unavailable. We're working to provide this information soon!

Post IPO Equity Funding Comparison Coming Soon

Stock Price

Growth & Insights and Company News

6 month growth

1 year growth

2 year growth

Yahoo Finance

Nov 5th, 2026

Lupin Q2 revenue up 11% to INR 7,827 crores as India grows 14.7%, but EBITDA margin falls to 25.1%

Lupin posted second-quarter revenue of INR 7,827 crores for fiscal 2027, up 11% from INR 7,048 crores a year earlier. India sales rose 14.7%, and other developed markets grew 46%. Profit margins fell. EBITDA margin dropped to 25.1% from 31.3%, as US revenue declined 13.4% from the previous quarter on new competition for Tolvaptan and Mirabegron. Employee costs rose about 29%. The company expects EBITDA margin of about 24-25% for the year. Chief executive officer Vinita Gupta aims to hold US revenue at "$1 billion plus" in fiscal 2028, with growth from Apixaban, Dalbavancin, and biosimilars. Net cash fell to INR 3,349 crores from INR 4,636 crores in March, after the Visiopharma acquisition and a dividend payout.

PR Newswire

Aug 20th, 2026

Lupin partners with Tenpoint to bring presbyopia eye drop YUVEZZI to Europe and UK

Lupin's subsidiary VISUfarma has secured exclusive rights to commercialise YUVEZZI, a once-daily presbyopia eye drop, across the EU, UK, Switzerland, Norway, and Iceland through a licensing agreement with Tenpoint Therapeutics' subsidiary Visus Therapeutics. Under the deal, VISUfarma will make a strategic investment in Visus. Tenpoint and Visus will be eligible for regulatory and commercial milestone payments plus tiered royalties based on net sales. YUVEZZI is the first FDA-approved dual-agent eye drop for presbyopia, combining carbachol and brimonidine tartrate. The treatment addresses a condition affecting approximately 2 billion people globally. The partnership strengthens Lupin's vision care franchise following its acquisition of VISUfarma. Tenpoint is advancing US commercialisation and has submitted regulatory applications in the UK, with plans for additional markets worldwide.

PR Newswire

Aug 17th, 2026

Lupin receives US FDA approval for generic Pitolisant tablets

Lupin Limited has received final approval from the US Food and Drug Administration for its generic Pitolisant Tablets in 4.45 mg and 17.8 mg strengths. The FDA approved Lupin's tablets as bioequivalent to Wakix for the indications in the approved labelling. Lupin is a Mumbai-based global pharmaceutical company that distributes products in over 100 markets. The company specialises in branded and generic formulations, complex generics, biotechnology products, and active pharmaceutical ingredients. It operates 15 manufacturing sites and six research centres globally, employing over 26,000 professionals.

PR Newswire

Jul 30th, 2026

Lupin launches generic Sugammadex injection in US after FDA approval

Lupin Limited has received US FDA approval and launched Sugammadex Injection in the United States. The product is available in two strengths: 200 mg/2 mL and 500 mg/5 mL single-dose vials. Sugammadex Injection is bioequivalent to Merck's Bridion Injection. It is indicated for reversing neuromuscular blockade induced by rocuronium bromide and vecuronium bromide in adults and paediatric patients aged 2 years and older undergoing surgery. Lupin is a Mumbai-based pharmaceutical company with products distributed in over 100 markets. The firm specialises in branded and generic formulations, complex generics, biotechnology products, and active pharmaceutical ingredients. It operates 15 manufacturing sites and 7 research centres globally, employing over 26,000 professionals.

Multibagg AI

Jul 2nd, 2026

Lupin subsidiary to acquire 43.38% stake in Philippines' MPPI for up to $39.6M by May 2026

Lupin Ltd announced its subsidiary Nanomi B.V. will acquire a 43.38% stake in Multicare Pharmaceuticals Philippines Inc for up to $39.6 million in cash, with completion expected by end-May 2026. The deal involves purchasing 11,794,497 shares from existing shareholders to strengthen Lupin's presence in the Philippines. Separately, MPPI executed a buyback of 2,813,811 shares using retained earnings. As Nanomi did not participate, its holding automatically increased from 51% to 56.28%. MPPI reported turnover of PHP 2,096.60 million and net worth of PHP 1,265.50 million as of 31 March 2025. Lupin's shares fell 2.52% in early trade on 2 April following the announcement, trading at ₹2,216.20 on BSE.

Recently Posted Jobs